Silence Therapeutics Plc American Depository Share
$12.20
Market Cap
$758.28M
Shares Outstanding
62.2M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Sep 8, 2020
Round Lot
100
Locale
US
Day Open
$12.59
Day High
$12.74
Day Low
$12.14
Volume
1.14M
VWAP
$12.36
Prev Close
$12.70
Transactions
--
Acc. Volume
--
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics Plc American Depository Share (SLN) closed the 2026-09-18 session at $12.20, down 3.94% versus the previous close (-0.50). The stock opened at $12.59 and traded between $12.14 and $12.74 during that session. Session trading volume was 1.1M shares. The volume-weighted average price (VWAP) is $12.36.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics Plc American Depository Share has a market capitalization of $758.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SLN is listed on the XNAS exchange. The company employs approximately 88 people. The recorded listing date is 2020-09-08.
On this page you can find market SLN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.